Analysis of efficacy of SGLT2 inhibitors using semi-mechanistic model

• Váldodahkkit: Oleg eDemin Jr (Dahkki), Tatiana eYakovleva (Dahkki), Dmitry eKolobkov (Dahkki), Oleg eDemin (Dahkki)
• Materiálatiipa: Girji
• Almmustuhtton: Frontiers Media S.A., 2014-10-01T00:00:00Z.
• Fáttát: article
• Liŋkkat: Connect to this object online.

Renal sodium-dependent glucose co-transporter 2 (SGLT2) is one of the most promising targets for the treatment of type 2 diabetes. Two SGLT2 inhibitors, dapagliflozin and canagliflozin, have already been approved for use in USA and Europe; several additional compounds are also being developed for th...